GENTICEL : 2014 Reference Document Available with Annual Financial Report

le
0

Genticel (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, announces that its reference document 2014 was registered, on March 31st, 2015, under the number R.15-015 by the AMF (Authorité des marchés financiers).

The 2014 reference document notably includes:

  • 2014 annual financial report;
  • the Supervisory Board's Chairman report as stipulated by Article L.225-68 of the French Commercial Code and the corresponding external auditor report;
  • the fees for external auditors;
  • the company's activities in terms of social, environmental and community impact.

This document *can be consulted on the Genticel website (www.genticel.com, Investors section) and on the AMF website (www.amf-france.org). Copies of the document are available upon request, free of charge, at the registered office of the Company, 516 Rue Pierre et Marie Curie, Prologue Biotech, 31670 Labège - France.
 

Note (*): Document only available in French at the date of registration


About Genticel
Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.

In 2015, Genticel licensed its Vaxiclase technology to Serum Institute of India Ltd. (SIIL), the largest vaccine producer in the world, for use as a component in acellular multivalent combination vaccines including pertussis antigens.

Genticel is based in Paris and Toulouse and was awarded 2014 "Prix Biotech d'Avenir" (Most
Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.

For more information, please visit Genticel's website, www.genticel.com
 


GENTICEL CONTACT
USA Investor Contact INVESTOR CONTACT PRESS CONTACT
Benedikt Timmerman 
Chief Executive Officer
investors@genticel.com
Brian Stollar
Tel.: +1 (212) 915 2577
bstollar@lifesciadvisors.com
 
Corinne Puissant
Tel.: +33 (0)1 53 67 36 77
cpuissant@actus.fr
 
Alexandra Prisa 
Tel.: +33 (0)1 53 67 36 90
aprisa@actus.fr
 

Information réglementée
Communiqués de mise à disposition de documents :
- Modalités de mise à disposition de document de référence ou de ses actualisations
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-39328-Genticel-MAD-DOC-DE-REF-VDEF-UK.pdf

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.


Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant